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Abstract
Introduction Rheumatoid arthritis (RA) is associated with
altered metabolism leading to muscle wasting. In the general
population, cigarette smoking is known to affect body
composition by reducing fat and inhibiting muscle synthesis.
Even though smoking has been implicated in the
pathophysiology and progression of RA, its possible effects on
body composition of such patients have not been studied. This
cross-sectional study aimed to identify potential associations of
smoking with body weight and composition of RA patients.
Methods A total of 392 patients (290 females) with RA were
assessed for body mass index (BMI), body fat (BF), fat-free
mass (FFM), and waist circumference. Erythrocyte
sedimentation rate, C-reactive protein, Disease Activity Score-
28, and Health Assessment Questionnaire score were used to
assess disease activity and severity. Smoking habit (current
smoker, ex-smoker, or never-smoker) and intensity (pack-years)
were also noted.
Results Current smokers had a significantly lower BMI
compared with ex-smokers (mean difference: male -2.6, 95%
confidence interval [CI]: -3.5 to -1.7; female: -2.6, 95% CI: -4.8
to -0.5) and never-smokers (mean difference: male -1.8, 95%
CI: -3 to -0.6; female: -1.4, 95% CI: -2.4 to -0.4). Similarly, the
BF of current smokers was lower compared with that of ex-
smokers (mean difference: male: -4.3, 95% CI: -7.5 to -1.2;
female: -3.4, 95% CI: -6.4 to -0.4) and never-smokers (mean
difference: male: -3.3, 95% CI: -6.3 to -0.4; female: -2.1, 95%
CI: -4 to -0.2). FFM did not differ between groups. Finally,
current smokers had a significantly smaller waist circumference
compared with ex-smokers only (mean difference: male: -6.2,
95% CI: -10.4 to -1.9; female: -7.8, 95% CI: -13.5 to -2.1).
Following adjustments for age, disease duration, and HAQ
score, smoking remained a significant predictor for BMI (P <
0.001), BF (P < 0.05), and waist circumference (P < 0.05).
Pack-years were inversely correlated with BF (r = -0.46; P <
0.001), and heavy smokers exhibited a significantly lower FFM
(P < 0.05) compared with all other participants.
Conclusion Within the limitations of a cross-sectional study, it
appears that cigarette smoking associates with reduced BMI
and BF in patients with RA and heavy smoking associates with
lower muscle mass. Smoking cessation appears to associate
with increased BMI, BF, and waist circumference in these
patients. These results should be confirmed in prospective
studies. Given the numerous adverse effects of smoking on
general health and RA, patients should be actively advised
against it. However, smoking cessation regimes in RA may need
to include more general lifestyle counselling, particularly about
weight control.Page 1 of 7
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ANCOVA = analysis of covariance; ANOVA = analysis of variance; BF = body fat; BMI = body mass index; CI = confidence interval; CRP = C-reactive 
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Rheumatoid arthritis (RA), the commonest inflammatory arthri-
tis, is associated with altered metabolism [1]. Compared with
healthy controls, RA patients exhibit elevated resting energy
expenditure (REE) and enhanced muscle catabolism [2]. Such
changes may lead to rheumatoid cachexia (that is, involuntary
loss of fat-free mass [FFM] with a proportional increase of
body fat [BF]) in the presence of stable body weight [3,4].
Body composition changes, particularly BF increase, may
remain largely undetected by traditional assessments such as
the body mass index (BMI) [5]. Increased BF, together with
reduced levels of physical activity due to joint inflammation and
damage [3,6], is associated with several comorbidities, includ-
ing cardiovascular disease [7,8] as well as increased mortality
[3].
Cigarette smoking is an important risk factor for several dis-
eases [9]. It is also known to decrease body weight in healthy
individuals by reducing appetite and increasing REE [10]. In
contrast, smoking cessation may associate with significant
weight increase, which constitutes a major deterrent to smok-
ing control [11].
We have recently demonstrated that smoking further
increases REE in RA [12] and this could potentially augment
rheumatoid cachexia in these patients. Given the RA-related
alterations in body composition and the comorbidity associ-
ated with them, the examination of potential contributors to
muscle wasting, such as smoking, is important. The aim of this
cross-sectional study was to detect potential associations
between smoking and body weight, body composition, and
rheumatoid cachexia in RA patients.
Materials and methods
Participants
Consecutive patients attending routine rheumatology clinics at
the Dudley Group of Hospitals NHS Trust, UK, were invited to
participate. All applicable institutional and governmental regu-
lations concerning the ethical use of human volunteers were
followed during this research. The study had local research
ethics committee and research and development directorate
approvals, and all volunteers provided informed consent. A
total of 400 volunteers (108 males and 292 females) with RA
(1987 revised American College of Rheumatology criteria
[13]) were assessed. Of them, 8 (6 males) were excluded from
the analyses due to missing data for body composition. Data
from the remaining 392 (median age: 63.1 [55.5 to 69.6]
years; median disease duration: 10 [4 to 18] years) were ana-
lysed.
Assessments
All volunteers were subjected to the same data collection pro-
cedures overseen by the same trained investigators. Standing
height was measured to the nearest 0.5 cm on a Seca 214
Road Rod portable stadiometer (Seca gmbh & co. kg., Ham-
burg, Germany). Body weight and composition (that is, BF and
FFM) were assessed using a Tanita BC- 418 MA Segmental
Body Composition Analyzer (Tanita Corporation, Tokyo,
Japan). After initial manual entry of their demographic details,
participants stood barefooted on the analyzer and held the
handgrips provided until the apparatus printed the results. BMI
was calculated on the basis of measured height and weight in
kilograms per square metre. Waist circumference was also
measured. Contemporary disease activity was assessed by
the erythrocyte sedimentation rate (ESR), C-reactive protein
(CRP), and the Disease Activity Score-28 (DAS28) [14]. The
Anglicised version of the 40-item Stanford Health Assessment
Questionnaire (HAQ) [15] was used to measure physical dys-
function as a proxy of disease severity. Patients' self-reported
smoking status and intensity (that is, pack-years) were noted.
Data management and analyses
Data were analysed using the Statistical Package for Social
Sciences version 15.0 (SPSS Inc., Chicago, IL, USA). A pre-
liminary evaluation of the variables using a Kolmogorov-Smir-
nov test of normality revealed that none of them required
transformation to reach normality. Mean ± standard deviation
was calculated for all variables. Differences in BMI, BF, and
FFM between smoking groups are presented as mean differ-
ences with 95% confidence intervals (CIs).
According to their smoking status, patients were grouped into
never-smokers, current smokers, and ex-smokers. Analysis of
variance (ANOVA) assessed differences in demographic char-
acteristics, BMI, and body composition between groups for
each gender. Analysis of covariance (ANCOVA) was
employed to determine whether the differences observed
were attributed to smoking status or other confounding factors
(for example, gender, age, and disease characteristics).
In the current smoker and ex-smoker groups, further associa-
tions between pack-years with BMI and body composition
were examined. Thereafter, patients in these groups were
divided into quartiles according to pack-years. ANOVA was
employed to assess differences in the measured variables
between these subgroups. ANCOVA was used to correct for
any confounding factors.
Thereafter, patients were grouped according to (a) RA-spe-
cific BMI [5] and (b) gender-specific BF [16] thresholds into
underweight, normal weight, overweight, and obese. Subse-
quently, they were grouped based on gender-specific cut-offPage 2 of 7
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FFM into low or normal FFM groups [18]. Chi-square analyses
were employed to assess differences between smoking
groups in the prevalence of overweight, obesity, high risk, and
low FFM. For all tests, the level of significance was set at a P
value of less than 0.05.
Results
Table 1 illustrates means ± standard deviations and the
ANOVA results for all studied parameters. Current smokers
had a significantly lower BMI than ex-smokers (mean differ-
ence: male -2.6, 95% CI: -3.5 to -1.7; female: -2.6, 95% CI: -
4.8 to -0.5) and never-smokers (mean difference: male -1.8,
95% CI: -3 to -0.6; female: -1.4, 95% CI: -2.4 to -0.4). Current
smokers also had a significantly lower BF compared with ex-
smokers (mean difference: male: -4.3, 95% CI: -7.5 to -1.2;
female: -3.4, 95% CI: -6.4 to -0.4) and never-smokers (mean
difference: male: -3.3, 95% CI: -6.3 to -0.4; female: -2.1, 95%
CI: -4 to -0.2). FFM did not differ between these groups (mean
difference: current smokers versus ex-smokers, male: -4.6,
95% CI: -10.7 to 1.6; female: -1.2; 95% CI: -3.8 to 1.4; cur-
rent smokers versus never-smokers, male: -2.7, 95% CI: -9.2
to 3.9; female: 0.1, 95% CI: -2.4 to 2.4). Current smokers had
a significantly smaller waist circumference than ex-smokers
(mean difference: male: -6.2, 95% CI: -10.4 to -1.9; female: -
7.8, 95% CI: -13.5 to -2.1) but not never-smokers (mean dif-
ference: male: -2.9, 95% CI: -10.6 to 4.9; female: -3.9, 95%
CI: -9.2 to 1.5). Also, ex-smokers had a larger waist circumfer-
ence than never-smokers but the difference was significant for
males only (mean difference: male: 3.3, 95% CI: 0.4 to 6.3;
female: 3.9, 95% CI: -0.4 to 8.1).
In ANCOVA with gender and smoking as factors and age,
DAS28, HAQ score, and disease duration as covariates,
smoking was a significant and independent predictor for BMI
(F2,387 = 8; P < 0.001), BF (F2,387 = 4.4; P < 0.05), and waist
circumference (F2,387 = 7.9; P < 0.001). Smoking also
emerged as a significant predictor of FFM (F2,387 = 5.1; P <
0.05), but inclusion of BMI as a covariate eliminated the effect
of smoking on FFM (P > 0.05).
There was a significant negative correlation between pack-
years and BF (r = -0.46; P < 0.001) in the current smoker and
the ex-smoker groups. This remained significant after adjust-
ment for gender, age, DAS28, HAQ score, and disease dura-
tion (F1,389 = 4.8; P < 0.05). Following pack-year grouping into
quartiles (pack-group), ANOVA did not reveal any differences
for BMI or body composition among the current and ex-smoker
pack-groups. However, an ANCOVA model with gender and
pack-group as factors and age and weight as covariates (fol-
lowing stepwise elimination of ESR, CRP, DAS28, HAQ
score, and disease duration) revealed a significant effect of
pack-group on FFM (F3,217 = 2.7; P < 0.05), with heavy smok-
ers exhibiting the lowest values. Mean (95% CI) values of this
variable in the pack-year subgroups appear in Figure 1.
Following BMI and BF grouping, chi-square analyses showed
significant differences (P < 0.05) in the prevalence of over-
Table 1
Measured variables of participants classified as current smokers (CS), ex-smokers (XS), and never-smokers (NS)
Gender Male (n = 102) Female (n = 290)
Smoking status CS XS NS CS XS NS
Number 20 50 32 49 97 144
Age, years 58.8 ± 8.1a 65.2 ± 9.9b 58.8 ± 15 57.4 ± 13.3a 64.1 ± 11.2b 60.7 ± 11.8
Height, cm 171.3 ± 7.1 174.3 ± 6.9 172.7 ± 7.7 160.9 ± 6.9 160.8 ± 6.8 159.5 ± 6.8
Weight, kg 76 ± 12.9b, c 85.8 ± 13.6 84.1 ± 14.8 67.5 ± 14.2a 74.8 ± 15.2 69.9 ± 13.6
Body mass index, kg/m2 25.8 ± 3.3b, c 28.4 ± 3.8 27.6 ± 4.6 26.1 ± 5.5a, b 28.6 ± 5.4 27.5 ± 5
Body fat, percentage 24.5 ± 6.4c, d 28.8 ± 6.8 27.8 ± 5.6 35.9 ± 7a, b 39.2 ± 6.5 38.1 ± 6.7
Fat-free mass, kg 57.2 ± 9.4 61.7 ± 7.7 59.8 ± 10.3 42.5 ± 4.8 43.7 ± 6.1 42.5 ± 6.1
Waist circumference, cm 100 ± 7.9c 106.2 ± 10.8b 102.9 ± 9.3 90.8 ± 12.8a 98.6 ± 13 94.7 ± 12.7
ESR, mm/hour 26.5 ± 20.5 22.8 ± 21.3 20.7 ± 19.7 30.5 ± 26 34.3 ± 32.7b 25.5 ± 19.8
C-reactive protein, mg/L 13.3 ± 9.4 16.1 ± 20.4 16 ± 24.3 21.9 ± 23.2b 21.4 ± 32.7b 11.9 ± 12.5
DAS28 4 ± 0.9 4.1 ± 1.5 3.9 ± 1.6 4.5 ± 1.5 4.3 ± 1.5 4.1 ± 1.2
HAQ score 0.9 ± 0.8 1.4 ± 1 1.1 ± 0.9 1.5 ± 0.9 1.5 ± 0.9 1.5 ± 0.9
Disease duration, years 8.6 ± 7.8 11.9 ± 10.6 14.6 ± 12.7 11.4 ± 9.8 13.5 ± 10.8 13.5 ± 11.1
Values are presented as mean ± standard deviation. aSignificant difference compared with XS (P < 0.05). bSignificant difference compared with 
NS (P < 0.05). cSignificant difference compared with XS (P < 0.001). dSignificant difference compared with NS (P < 0.001). DAS28, Disease 
Activity Score-28; ESR, erythrocyte sedimentation rate; HAQ, Health Assessment Questionnaire.Page 3 of 7
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more prevalent in ex-smokers (50%) followed by never-smok-
ers (39%) and current smokers (30%). Similarly, ex-smokers
had a significantly (P < 0.05) higher prevalence of increased
waist circumference (69%) compared with never-smokers
(60%) and current smokers (49%). However, FFM did not dif-
fer between groups (P > 0.05) (Figure 2).
Discussion
To our knowledge, this is the first study to identify significant
associations between smoking, body weight, and body com-
position of RA patients: current smokers had a significantly
lower BMI and BF compared with never-smokers. Both BMI
and BF were significantly increased in ex-smokers, whereas
very heavy smoking appeared to associate with reduced FFM.
The study has several potential limitations. These are all cross-
sectional associations, and although they can serve for
hypothesis generation, they do not provide definitive evidence
for causality or directionality: longitudinal studies are required
for this. In addition, body composition was assessed by bioe-
lectrical impedance. This method has been validated [19-23]
and is thought to be suitable for body composition studies in
diverse populations [22-25], correlates well with the 'gold
standards' of dual-energy x-ray absorptiometry and hydrostatic
weighing [23], and is widely used in RA research
[5,12,24,26,27], but it has not actually been specifically vali-
dated in the RA population. Finally, although self-report of
smoking, especially smoking history, is generally reliable, both
under- and over-reporting can occur [28]. This is unlikely to
have influenced the primary findings of this study (that is, the
differences between current, ex-, and non-smokers), while any
misreporting in pack-years may have been smoothed by the
large number of participants. It is difficult to assess any other
selection bias: the prevalence of current, ex-, and non-smokers
among the participants of this study was similar to that
reported for local general population subjects of similar age
[29], although it was different from an RA cohort established
more than 10 years ago [30].
Our observations for BMI are consistent with those in the gen-
eral population. Both male and female smokers tend to have
decreased BMI compared with their non-smoking counter-
parts [10,31]. In contrast, significant BMI increases have been
noted after smoking cessation [11]. Smokers have increased
levels of leptin [32], which regulates food intake and fat depo-
sition [33], and reduced hypothalamic neuropeptide Y [34],
which regulates appetite [35]. Smoking-induced increases in
the levels of epinephrine, norepinephrine, and thyroid hor-
mones lead to increased energy expenditure at rest [36,37]
and during light physical activity [38-40]. However, these
effects are short-lived: after smoking cessation, leptin
decreases to levels below those expected for non-smokers of
similar weight [32] and resting energy expenditure (REE)
returns to normal [41].
In patients with RA, smoking has been shown to elevate REE
[12]; however, no data are available on other potential contrib-
utors to smoking-related weight loss or smoking cessation-
Figure 1
Fat-free mass for males (a) and females (b) according to pack-year grouping. Data are presented as means with 95% confidence intervals. Pack-
year groups: 1, 1 to 9 pack-years; 2, 10 to 19 pack-years; 3, 20 to 34 pack-years; 4, greater than 35 pack-years. Asterisk indicates significant differ-
ence compared with group 1 (P < 0.05).Page 4 of 7
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Available online http://arthritis-research.com/content/10/3/R59related weight gain for this population. Although we did not
assess energy intake and expenditure or related regulators
(such as leptin), it is likely that the mechanisms behind the
reduced body weight of current smokers and the increased
body weight of ex-smokers with RA are similar to those
described for the general population.
Interestingly, the lower BMI of current smokers in the present
study seems to be due to decreased BF rather than FFM. A
possible mechanism by which smoking may affect fat metabo-
lism is through a reduction in neuropeptide Y. This molecule
not only stimulates food intake, but also promotes white fat
lipid storage and decreases brown fat thermogenesis [35], so
its inhibition through smoking would be expected to have the
opposite effects. Additionally, smoking results in decreased
adipose tissue lipoprotein lipase activity [42], which diverts fat
storage away from adipose tissue and toward utilization by
muscle [43], possibly leading to the decreased BF of smokers
[42,44]. In the present study, the inverse association between
smoking and BF appeared to be dose-dependent: increasing
pack-years associated with reducing BF levels. Smoking ces-
sation is thought to result in a reversal of the mechanisms
described above, leading to increases in BF [42] and, most
importantly, abdominal fat [45]. Indeed, among these RA
patients, ex-smokers seemed to be the most 'unhealthy' group
in terms of body weight and composition as they exhibited the
highest BMI, BF, and waist circumference values.
In predominantly healthy people who are from the general pop-
ulation and who do not have wasting muscle disease, smoking
of any intensity has been implicated in muscle wasting [10] by
impairing the process of muscle protein synthesis [46]. In con-
trast, in the present study, only very heavy smoking appeared
to associate with a reduction in FFM. It is possible that the
effect of smoking on muscle is of less significance than the
muscle loss associated with RA itself, as part of rheumatoid
cachexia. This hypothesis is supported by the finding that
increased duration of smoking (that is, pack-years) associated
with lower FFM in both current and ex-smokers, which sug-
gests the existence of a threshold below which smoking does
Figure 2
Prevalence of overweight and obesity, increased waist circumference, and low fat-free mass in smoking groups. (a) Prevalence of overweight and 
obesity based on rheumatoid arthritis (RA)-specific body mass index for current, ex-, and never-smokers. (b) Prevalence of overweight and obesity 
based on body fat for current, ex-, and never-smokers. (c) Prevalence of high risk based on waist circumference for current, ex-, and never-smokers. 
(d) Prevalence of low fat-free mass for current, ex-, and never-smokers. Chi-square analyses identified significant defences among smoking groups 
for prevalence of (a) overweight and obesity based on body mass index (P < 0.05), (b) overweight and obesity based on body fat (P < 0.05), and 
(c) increased waist circumference (P < 0.05). Prevalence of low fat-free mass did not differ between groups (P > 0.05).Page 5 of 7
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study of the impact of smoking intensity (and cessation) on the
body composition of patients with RA may throw more light on
the mechanistic basis of these observations.
Overall, this study suggests that, in RA, smoking associates
with reduced body mass and fatness without inducing further
muscle loss, except in very heavy smokers; in contrast, smok-
ing cessation associates with increased body mass and fat-
ness. This should not be interpreted as favouring what is a very
unhealthy habit. Smoking cessation, even if it occurs in mid-
life, reduces most of the later risk of death from tobacco [47].
However, smoking cessation is known to result in body weight
increase, and this may affect some people's decision to stop
smoking [11,44,45]. Therefore, any smoking cessation regime
should be underpinned by more generalised lifestyle counsel-
ling, including advice on exercise and weight management.
This is emphasized by the fact that, based on recently
described RA-specific BMI [5], BF [16], and waist circumfer-
ence thresholds [48], ex-smokers have the highest prevalence
of obesity – both total and abdominal. FFM did not differ
between groups and the prevalence of low FFM was compa-
rable to that expected in age- and gender-matched healthy
individuals [18].
Conclusion
Within the limitations of this study, it is concluded that RA
smokers have a lower BMI and BF than RA non-smokers, while
heavy smokers also have a reduced FFM. A history of smoking
cessation appears to associate with increases in BMI, BF, and
waist circumference. Nevertheless, given the numerous
adverse effects of smoking on health, smokers with RA should
be actively advised against it, but smoking cessation programs
should include wider lifestyle counselling for weight control,
also focusing on increased physical activity and a healthy diet.
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